Sterling Financial Planning Inc. Raises Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Sterling Financial Planning Inc. lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 857 shares of the company’s stock after acquiring an additional 20 shares during the quarter. Sterling Financial Planning Inc.’s holdings in Eli Lilly and Company were worth $500,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Lipe & Dalton bought a new position in Eli Lilly and Company during the fourth quarter valued at $26,000. Thompson Investment Management Inc. bought a new position in shares of Eli Lilly and Company in the third quarter worth $27,000. Retirement Group LLC boosted its holdings in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares during the period. Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company in the third quarter worth $35,000. Finally, Optiver Holding B.V. bought a new position in shares of Eli Lilly and Company in the third quarter worth $36,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Down 0.6 %

Eli Lilly and Company stock traded down $4.82 during trading hours on Thursday, hitting $745.95. 1,701,145 shares of the stock traded hands, compared to its average volume of 3,067,708. The firm’s 50-day moving average price is $764.03 and its two-hundred day moving average price is $657.67. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company has a market cap of $708.77 billion, a PE ratio of 129.32, a PEG ratio of 1.63 and a beta of 0.34. Eli Lilly and Company has a one year low of $367.35 and a one year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the previous year, the firm posted $2.09 EPS. The business’s revenue for the quarter was up 28.1% compared to the same quarter last year. On average, research analysts forecast that Eli Lilly and Company will post 12.52 EPS for the current year.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of analyst reports. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Citigroup increased their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. BMO Capital Markets increased their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Bank of America increased their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.